Skip to main content

Advertisement

SpringerLink
Log in

CNTO 95, a fully human anti αv integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells

  • Research Paper
  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

Abstract

CNTO 95 is a fully human monoclonal antibody that recognizes αv integrins. Previous studies have shown that CNTO 95 exhibits both anti-tumor and anti-angiogenic activities (Trikha M et al., Int J Cancer 110:326–335, 2004). In this study we investigated the biological activities of CNTO 95 on breast tumor cells both in vitro and in vivo. In vitro treatment with CNTO 95 decreased the viability of breast tumor cells adhering to vitronectin. CNTO 95 inhibited tumor cell adhesion, migration, and invasion in vitro. CNTO 95 treatment also induced tyrosine dephosphorylation of focal adhesion kinase (FAK), and the docking protein paxillin that recruits both structural and signaling molecules to focal adhesions (Turner CE, Int J Biochem Cell Biol 30:955–959, 1998; O’Neil GM et al., Trends Cell Biol 10:111–119, 2000). These results suggest that CNTO 95 inhibits breast tumor cell growth, migration and invasion by interruption of αv integrin mediated focal adhesions and cell motility signals. In vivo studies of CNTO 95 were conducted in an orthotopic breast tumor xenograft model. Treatment with CNTO 95 resulted in significant inhibition of both tumor growth and spontaneous metastasis of MDA-MB-231 cells to the lungs. CNTO 95 also inhibited lung metastasis in a separate experimental (tail vein injection) model of metastasis. The results presented here demonstrate the anti-tumor and anti-metastatic activities of CNTO 95 in breast cancer models and provide insight into the cellular and molecular mechanisms mediating its inhibitory effects on metastasis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Hynes RO (2002) Integrins: bidirectional, allosteric signaling machines. Cell 110:673–687

    Article  PubMed  CAS  Google Scholar 

  2. Juliano RL, Reddig P, Alahari S, Edin M, Howe A, Aplin A (2004) Integrin regulation of cell signalling and motility. Biochem Soc Trans 32:443–446

    Article  PubMed  CAS  Google Scholar 

  3. Kageshita T, Hamby CV, Hirai S, Kimura T, Ono T, Ferrone S (2000) Differential clinical significance of alpha(v) Beta(3) expression in primary lesions of acral lentiginous melanoma and of other melanoma histotypes. Int J Cancer 89:153–159

    Article  PubMed  CAS  Google Scholar 

  4. Arihiro K, Kaneko M, Fujii S, Inai K, Yokosaki Y (2000) Significance of alpha 9 beta 1 and alpha v beta 6 integrin expression in breast carcinoma. Breast Cancer 7:19–26

    Article  PubMed  CAS  Google Scholar 

  5. Markovic-Lipkovski J, Brasanac D, Muller GA, Muller CA (2001) Cadherins and integrins in renal cell carcinoma: an immunohistochemical study. Tumor 87:173–178

    CAS  Google Scholar 

  6. Goldberg I, Davidson B, Reich R, Gotlieb WH, Ben-Baruch G, Bryne M, Berner A, Nesland JM, Kopolovic J (2001) Alphav integrin expression is a novel marker of poor prognosis in advanced-stage ovarian carcinoma. Clin Cancer Res 7:4073–4079

    PubMed  CAS  Google Scholar 

  7. Kawashima A, Tsugawa S, Boku A, Kobayashi M, Minamoto T, Nakanishi I, Oda Y (2003) Expression of alphav integrin family in gastric carcinomas: increased alphavbeta6 is associated with lymph node metastasis. Pathol Res Pract 199:57–64

    Article  PubMed  CAS  Google Scholar 

  8. Sato T, Konishi K, Maeda K, Yabushita K, Miwa A (2003) Integrin alpha v, c-erbB2 and DNA ploidy in lung metastases from colorectal cancer. Hepatogastroenterology 50:27–30

    PubMed  Google Scholar 

  9. Cooper CR, Chay CH, Pienta KJ (2002) The role of alpha(v)beta(3) in prostate cancer progression. Neoplasia 4:191–194

    Article  PubMed  CAS  Google Scholar 

  10. Hapke S, Kessler H, Luber B, Benge A, Hutzler P, Hofler H, Schmitt M, Reuning U (2003) Ovarian cancer cell proliferation and motility is induced by engagement of integrin alpha(v)beta3/Vitronectin interaction. Biol Chem 384:1073–1083

    Article  PubMed  CAS  Google Scholar 

  11. Stupack DG, Cheresh DA (2004) Integrins and angiogenesis. Curr Top Dev Biol 64:207–238

    Article  PubMed  CAS  Google Scholar 

  12. Wittekind C, Neid M (2005) Cancer invasion and metastasis. Oncology 69(Suppl 1):14–16

    Article  PubMed  Google Scholar 

  13. Bartsch JE, Staren ED, Appert HE (2003) Adhesion and migration of extracellular matrix-stimulated breast cancer. J Surg Res 110:287–294

    Article  PubMed  CAS  Google Scholar 

  14. Vacca A, Ria R, Presta M, Ribatti D, Iurlaro M, Merchionne F, Tanghetti E, Dammacco F (2001) Alpha(v)beta(3) integrin engagement modulates cell adhesion, proliferation, and protease secretion in human lymphoid tumor cells. Exp Hematol 29:993–1003

    Article  PubMed  CAS  Google Scholar 

  15. Parsons JT (2003) Focal adhesion kinase: the first ten years. J Cell Sci 116:1409–1416

    Article  PubMed  CAS  Google Scholar 

  16. Parsons JT, Martin KH, Slack JK, Taylor JM, Weed SA (2000) Focal adhesion kinase: a regulator of focal adhesion dynamics and cell movement. Oncogene 19:5606–5613

    Article  PubMed  CAS  Google Scholar 

  17. Mitra SK, Hanson DA, Schlaepfer DD (2005) Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 6:56–68

    Article  PubMed  CAS  Google Scholar 

  18. Turner CE (2000) Paxillin interactions. J Cell Sci 113(Pt 23):4139–4140

    PubMed  CAS  Google Scholar 

  19. Trikha M, Zhou Z, Nemeth JA, Chen Q, Sharp C, Emmell E, Giles-Komar J, Nakada MT (2004) CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo. Int J Cancer 110:326–335

    Article  PubMed  CAS  Google Scholar 

  20. Veryard C (2006) AACR-NCI-EORTC–17th symposium: molecular targets and cancer therapeutics. 14–18th November 2005, Philadelphia, PA, USA. IDrugs 9:1–3

    PubMed  Google Scholar 

  21. Atienza JM, Zhu J, Wang X, Xu X, Abassi Y (2005) Dynamic monitoring of cell adhesion and spreading on microelectronic sensor arrays. J Biomol Screen 10:795–805

    Article  PubMed  CAS  Google Scholar 

  22. Hood JD, Cheresh DA (2002) Role of integrins in cell invasion and migration. Nat Rev Cancer 2:91–100

    Article  PubMed  Google Scholar 

  23. Aznavoorian S, Stracke ML, Parsons J, McClanahan J, Liotta LA (1996) Integrin alphavbeta3 mediates chemotactic and haptotactic motility in human melanoma cells through different signaling pathways. J Biol Chem 271:3247–3254

    Article  PubMed  CAS  Google Scholar 

  24. Voura EB, Ramjeesingh RA, Montgomery AM, Siu CH (2001) Involvement of integrin alpha(v)beta(3) and cell adhesion molecule L1 in transendothelial migration of melanoma cells. Mol Biol Cell 12:2699–2710

    PubMed  CAS  Google Scholar 

  25. Frame MC (2004) Newest findings on the oldest oncogene; how activated src does it. J Cell Sci 117:989–998

    Article  PubMed  CAS  Google Scholar 

  26. Turner CE (1998) Paxillin. Int J Biochem Cell Biol 30:955–959

    Article  PubMed  CAS  Google Scholar 

  27. O’Neill GM, Fashena SJ, Golemis EA (2000) Integrin signalling: a new Cas(t) of characters enters the stage. Trends Cell Biol 10:111–119

    Article  PubMed  CAS  Google Scholar 

  28. Schlaepfer DD, Mitra SK, Ilic D (2004) Control of motile and invasive cell phenotypes by focal adhesion kinase. Biochim Biophys Acta 1692:77–102

    PubMed  CAS  Google Scholar 

  29. Price JE, Polyzos A, Zhang RD, Daniels LM (1990) Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res 50:717–721

    PubMed  CAS  Google Scholar 

  30. Tucker GC (2006) Integrins: molecular targets in cancer therapy. Curr Oncol Rep 8:96–103

    Article  PubMed  CAS  Google Scholar 

  31. Hanks SK, Ryzhova L, Shin NY, Brabek J (2003) Focal adhesion kinase signaling activities and their implications in the control of cell survival and motility. Front Biosci 8:d982–d996

    Article  PubMed  CAS  Google Scholar 

  32. Tilghman RW, Slack-Davis JK, Sergina N, Martin KH, Iwanicki M, Hershey ED, Beggs HE, Reichardt LF, Parsons JT (2005) Focal adhesion kinase is required for the spatial organization of the leading edge in migrating cells. J Cell Sci 118:2613–2623

    Article  PubMed  CAS  Google Scholar 

  33. Brown MC, Cary LA, Jamieson JS, Cooper JA, Turner CE (2005) Src and FAK kinases cooperate to phosphorylate paxillin kinase linker, stimulate its focal adhesion localization, and regulate cell spreading and protrusiveness. Mol Biol Cell 16:4316–4328

    Article  PubMed  CAS  Google Scholar 

  34. Cohen LA, Guan JL (2005) Mechanisms of focal adhesion kinase regulation. Curr Cancer Drug Targets 5:629–643

    Article  PubMed  CAS  Google Scholar 

  35. McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG, Frame MC (2005) The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nat Rev Cancer 5:505–515

    Article  PubMed  CAS  Google Scholar 

  36. Sein TT, Thant AA, Hiraiwa Y, Amin AR, Sohara Y, Liu Y, Matsuda S, Yamamoto T, Hamaguchi M (2000) A role for FAK in the Concanavalin A-dependent secretion of matrix metalloproteinase-2 and -9. Oncogene 19:5539–5542

    Article  PubMed  CAS  Google Scholar 

  37. Schaller MD (2004) FAK and paxillin: regulators of N-cadherin adhesion and inhibitors of cell migration? J Cell Biol 166:157–159

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

We thank Paul Marsters for his help in statistical analysis and Ray Heslip for his help preparing graphs.

Author information

Authors and Affiliations

  1. Oncology Research, Centocor R&D, Inc., 145 King of Prussia Road, Radnor, PA, 19087, USA

    Qiming Chen, Carol D. Manning, Hillary Millar, Francis L. McCabe, Catherine Ferrante, Celia Sharp, Lillian Shahied-Arruda, Parul Doshi, Marian T. Nakada & G. Mark Anderson

Authors
  1. Qiming Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carol D. Manning
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hillary Millar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Francis L. McCabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Catherine Ferrante
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Celia Sharp
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lillian Shahied-Arruda
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Parul Doshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Marian T. Nakada
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. G. Mark Anderson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Qiming Chen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chen, Q., Manning, C.D., Millar, H. et al. CNTO 95, a fully human anti αv integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells. Clin Exp Metastasis 25, 139–148 (2008). https://doi.org/10.1007/s10585-007-9132-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10585-007-9132-4

Keywords

Search

Navigation